SUSMED,Inc. AI Stock Analysis
Want to see JP:4263 full AI Analyst Report?
SUSMED,Inc. (4263) AI Stock Analysis
SUSMED,Inc.
(TSE/TYO:4263)
SUSMED scores near the low end of the range. The dominant drag is financial performance: deepening net losses (-¥383M) and record cash burn (-¥549M free cash flow) in FY2026, with operating expenses outpacing an otherwise strong 81% revenue rebound. The debt-free balance sheet and ¥4.07B equity cushion provide real downside protection and several years of runway, but equity is steadily being consumed. Technicals reinforce the caution, with the price far below all key moving averages and negative MACD confirming a sustained downtrend, though extremely low RSI and Stochastic readings suggest selling has become stretched. Valuation offers no anchor given negative earnings and no dividend. The investment case hinges on whether revenue can scale to cover the cost base before the balance sheet cushion erodes.
SUSMED,Inc. (4263) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.27B
- Dividend Yield
- ―
- Average Volume (3M)
- 155.37K
- Price to Earnings (P/E)
- -9.1
- Beta (1Y)
- 1.01
- Revenue Growth
- 42.52%
- EPS Growth
- -81.61%
- Country
- Japan
- Employees
- 50
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
SUSMED,Inc. Business Overview & Revenue Model
Company Description
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast...
SUSMED,Inc. Financial Statement Overview
Summary
Financials are weak overall. The income statement (score 25) shows persistent and widening losses, with a net loss of ¥383M in FY2026 despite revenue rebounding ~81% to ¥497M; operating costs are scaling faster than sales and the company has never reached operating profitability. Cash flow (score 18) is the biggest concern, with operating cash flow of -¥474M and free cash flow of -¥549M in FY2026, the worst on record and an accelerating burn. The balance sheet (score 72) is the offsetting strength: zero debt, a 0.0 debt-to-equity ratio, and ¥4.07B of equity provide meaningful runway, though equity has eroded from ¥4.87B in FY2023 as losses accumulate. Excellent ~96-97% gross margins highlight the asset-light model, but scale remains far too small to cover the cost base.
Income Statement
25NegativeBalance Sheet
72PositiveCash Flow
18Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 679.26M | 497.21M | 462.99M | 342.58M | 316.87M | 530.65M |
| Gross Profit | 650.78M | 479.82M | 450.72M | 330.85M | 306.50M | 522.67M |
| EBITDA | -241.92M | -319.99M | -289.22M | -350.22M | -231.11M | -43.99M |
| Net Income | -465.37M | -382.69M | -298.40M | -357.42M | -233.48M | -50.75M |
Balance Sheet | ||||||
| Total Assets | 4.19B | 4.22B | 4.50B | 4.93B | 4.94B | 5.10B |
| Cash, Cash Equivalents and Short-Term Investments | 3.95B | 3.70B | 4.40B | 4.85B | 4.90B | 5.05B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 301.93M | 147.94M | 132.33M | 327.79M | 93.34M | 230.33M |
| Stockholders Equity | 3.89B | 4.07B | 4.37B | 4.60B | 4.85B | 4.87B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -548.50M | -436.79M | -240.04M | -177.90M | 82.40M |
| Operating Cash Flow | 0 | -474.45M | -432.48M | -230.76M | -165.28M | 100.59M |
| Investing Cash Flow | 0 | -228.13M | -19.97M | -8.53M | -20.36M | -18.19M |
| Financing Cash Flow | 0 | 2.75M | 3.67M | 37.37M | 3.46B | 62.36M |
SUSMED,Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4263, the sentiment is Negative. The current price of 252.00 is below the 20-day moving average (MA) of 319.65, below the 50-day MA of 378.42, and below the 200-day MA of 726.12, indicating a bearish trend. The MACD of -40.95 indicates Positive momentum. The RSI at 16.15 is Positive, neither overbought nor oversold. The STOCH value of 6.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4263.
SUSMED,Inc. Peers Comparison
Overall Rating
JP:241378.5Outperform
JP:448372Outperform
JP:443854Neutral
JP:448054Neutral
JP:426338Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | JPY 1.24T | 26.54 | 11.33% | 1.20% | 9.48% | 2.08% | |
| 72Outperform | JPY 244.77B | 33.34 | ― | 0.48% | 20.50% | 19.27% | |
| 54Neutral | JPY 2.34B | -4.39 | ― | ― | 14.84% | 30.67% | |
| 54Neutral | JPY 67.05B | 38.48 | 11.30% | ― | 21.01% | 10.15% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 38Underperform | JPY 4.27B | -9.13 | ― | ― | 42.52% | -81.61% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4263 | SUSMED,Inc. | 252.00 | -658.00 | -72.31% | |
| JP:2413 | M3 | 1832.00 | -805.80 | -30.55% | |
| JP:4480 | Medley, Inc. | 2108.00 | -447.00 | -17.50% | |
| JP:4438 | Welby Inc. | 274.00 | -57.00 | -17.22% | |
| JP:4483 | JMDC Inc. | 3740.00 | -514.30 | -12.09% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
